Treatment Of Chronic Heart Failure Flashcards

(32 cards)

0
Q

Non-pharmacological interventions

A

Risk factor modification (smoking, drinking, weight)
Limiting sodium and water intake
Limiting travel to high altitudes or humid environments
Regular influenza/pneumococcal vaccines

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
1
Q

Treatments of chronic heart failure

A

Non-pharmacological methods
Drug treatments
Assistive devices

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Describe the NYHA classes of breathlessness

A

Class 1 - No limitation
Class 2 - Symptoms on normal exercise
Class 3 - Symptoms on slight exercise
Class 4 - Symptoms at rest

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

First line treatment of left ventricle systolic dysfunction

A

ACE inhibitors and Beta-blockers

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Second line treatment for left ventricular systolic dysfunction

A

Aldosterone Anagonist if NYHA III - IV or recent MI
ARB if NYHA II - III
Hydrazine in combination with a nitrate if black and NYHA III - IV

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Ivabradine

A

Inhibits the funny ion channel (not kidding!!) in the SAN and AVN (mixed Na+/K+ channel)
5-7.5mg BD

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Cardiac rehabilitation

A

Effective for stable patients if supervised group based programme incorporating educational and psychological elements

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

ACE inhibitors in HF

A

First line treatment in HF-REF with or without symptoms
If congested start ACEi and diuretic
Must check renal function as dose is titrated to effected dose

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Efficacy of ACEis in HF

A

20-25% reduction in mortality and hospitalisation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Complications of ACEis in HF

A

Decreasing renal function - discontinue if creat increases by >50% or >200 or potassium >6
Hypotension - ignore if asymptomatic, if problematic stop other vasodilators and reduce diuretics first
Cough - exclude significant pulmonary cause and shift to ARBs if troublesome

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Beta-blockers in HF

A

Symptomatic and prognostic benefit for patient of all backgrounds NYHA II - III
Carvedilol, Nebivolol, Bisoprolol, Metoprolol

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Cardioselective Beta-blockers

A

Metoprolol, Bisoprolol and Nebivolol

Safe in COPD and mild to moderate PVD

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Vasodilating Beta- blockers

A

Nebivolol and Carvedilol

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Beta-blocker dosing

A

If problematic switch to double doses at two week intervals
Small doses still give benefit, don’t increase dose if patient becomes bradycardic
Symptomatic improvement takes 3-6 months

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

When should diuretics be used in HF?

A

Only if patient shows signs of fluid overload
If patient dose not respond used twice daily IV infusions

Bumetanide gives a possible advantage if signs of right sided HF

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

When should Aldosterone receptor Antagonists (Spirolactone) be added?

A

All patients with NYHA II-IV symptoms as it improves symptoms and rate of survival
In all cases of HF post MI
Spirolactone found to give 30% relative risk reduction in patients with NYHA III-IV symptoms

16
Q

Possible complications of Aldosterone receptor antagonists

A

Risk of a hyperkalaemic renal failure - check regularly and reduce/stop if K above 5.5 or creatinine >200

Risk of GI upsets/bleeds

17
Q

Angiotensin II receptor blockers (ARBs, Losartan) should be used when

A

When patients are ACEi intolerant due to cough, similar in efficacy and risk reduction
Can be used in combination with ACEi in symptomatic patients

18
Q

Digoxin

A

In patients suffering AF with any level of HF
Greatest effect from combination of digoxin and beta-blocker
Reduces admissions in severe HF, but does not reduce mortality

19
Q

Digoxin interacts with

A

Verapamil, Amiodarone, Propafenone, Erythromycin, Omeprazole, Tetracycline

20
Q

Hydralazine and nitrates are used

A

In patients who are intolerant of ACEi and ARBs due to cough or renal impairment
Reduces mortality
Has additional benefit in black populations, is possible that combination prevents nitrate tolerance

21
Q

Use of anti thrombotic agents in HF

A

Little evidence
Warfarin in patients with AF
Avoid aspirin unless evidence of vascular disesae

22
Q

Calcium channel blockers in HF

A

Avoid Diltiazem and Verapamil

Felodipine and Amlodipine have little/no effect

23
Q

Nesiritide

A

Is a recombinant ANP which works the renin-angiotensin system
Was initially believed to be helpful but no evidence is helpful
Possibly harmful

24
What are vaptans?
Vasopressin receptor antagonists which are promising drugs in development
25
Endothelin antagonists
Are useful in pulmonary hypertension but not in standard HF
26
Statins
Like aspirin Aee useful if there is an underlying ischeamic cause but not otherwise
27
The treatment of diastolic HF
Largely the same as systolic dysfunction Evidence base for Nebivolol and candesartan (ARBs) Don't over-diurese and avoid tachycardia Focus treatment on hypertension
28
Devices used to treat chronic HF
CRT pacemaker | CRT defibrillator
29
Cardiac resynchronisation therapy (CRT) pacemaker
Used in HF patients with evidence of desynchrony | 36% reduction in mortality above maximal medical therapy
30
Cardiac resynchronisation therapy (CRT) defibrillator
Same as a pacemaker but used in patients at risk of SVT/VT/VF and is able to shock the patient if these rhythms occur
31
Ranolazine
Used in angina Inhibits late Na+ current No haemodynamic effects or bradycardia